Asia Pac Allergy.  2014 Oct;4(4):230-240. 10.5415/apallergy.2014.4.4.230.

The role of antiseptic agents in atopic dermatitis

• Lee M
• Van Bever

• KMID: 2397104
• DOI: http://doi.org/10.5415/apallergy.2014.4.4.230

Abstract

The skin of individuals with atopic dermatitis has a susceptibility to be colonized with Staphylococcus aureus. This has been associated with increased frequency and severity of exacerbations of atopic dermatitis. Therefore, there is a growing interest in the use of antiseptic agents to target primary bacterial colonization and infection. Antiseptic agents have been found to be better tolerated and less likely to induce bacterial resistance as compared to antibiotics. There is also a wide variety of antiseptic agents available. The efficacy of antiseptic agents has yet to be established as the studies reviewed previously have been small and of suboptimal quality. This review discusses the rationale behind targeting S. aureus with antiseptic agents and presents findings from a review of studies assessing the efficacy of antiseptics in atopic dermatitis in the last five years. Four studies were found, including a bleach bath study which has already been reviewed elsewhere. The remaining 3 studies assessed the efficacy of sodium hypochlorite containing cleansing body wash, sodium hypochlorite baths and 1% triclosan in leave on emollient. These studies suggested some benefit for the inclusion of antiseptic use with the mainstay management of atopic dermatitis, including a potential steroid sparring effect. However, there are many limitations to these studies which therefore warrant further investigation on the impact of antiseptic use in atopic dermatitis.

Keyword

Staphylococcus aureus; Atopic dermatitis; Anti-infective agents, local

MeSH Terms

Anti-Bacterial Agents
Anti-Infective Agents, Local
Baths
Colon
Dermatitis, Atopic*
Skin
Sodium Hypochlorite
Staphylococcus aureus
Triclosan
Anti-Bacterial Agents
Anti-Infective Agents, Local
Sodium Hypochlorite
Triclosan

Reference

1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009; 124:1251–1258.e23.

2. Flohr C. Recent perspectives on the global epidemiology of childhood eczema. Allergol Immunopathol (Madr). 2011; 39:174–182.

3. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008; 121:947–954.e15.

4. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980; 92:Suppl. 44–47.

5. National Institute for Health and Care Excellence. NICE guidelines [CG57]. Atopic eczema in children: management of atopic eczema in children from birth up to the age of 12 years. London: NICE;c2014. cited 2014 Mar 9. Available from: http://guidance.nice.org.uk/CG57/Guidance/pdf/English.

6. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013; 24:476–486.

7. Cox H, Lloyd K, Williams H, Arkwright PD, Brown T, Clark C, Campbell M, Gore C, Hardman C, Langford A, Lewis-Jones S, Lawton S, Ridd M, Russell L, Sohi D, Turnbull R, Venter C, Warner JO. Science and Research Department, Royal College of Paediatrics and Child Health. Emollients, education and quality of life: the RCPCH care pathway for children with eczema. Arch Dis Child. 2011; 96:Suppl 2. i19–i24.

8. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010; 125:4–13.

9. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003; 361:151–160.

10. Farhi D, Taieb A, Tilles G, Wallach D. The historical basis of a misconception leading to undertreating atopic dermatitis (eczema): facts and controversies. Clin Dermatol. 2010; 28:45–51.

11. Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, Yi D, Zhao B. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006; 155:680–687.

12. Lin YT, Wang CT, Chiang BL. Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol. 2007; 33:167–177.

13. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974; 90:525–530.

14. Leyden JJ, Kligman AM. The case for steroid: antibiotic combinations. Br J Dermatol. 1977; 96:179–187.

15. Aly R, Maibach HI, Shinefield HR. Microbial flora of atopic dermatitis. Arch Dermatol. 1977; 113:780–782.

16. Mempel M, Lina G, Hojka M, Schnopp C, Seidl HP, Schafer T, Ring J, Vandenesch F, Abeck D. High prevalence of superantigens associated with the egc locus in Staphylococcus aureus isolates from patients with atopic eczema. Eur J Clin Microbiol Infect Dis. 2003; 22:306–309.

17. Breuer K, HAussler S, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol. 2002; 147:55–61.

18. Hon KL, Lam MC, Leung TF, Kam WY, Li MC, Ip M, Fok TF. Clinical features associated with nasal Staphylococcus aureus colonisation in Chinese children with moderate-to-severe atopic dermatitis. Ann Acad Med Singapore. 2005; 34:602–605.

19. Falanga V, Campbell DE, Leyden JJ, Douglas SD. Nasal carriage of Staphylococcus aureus and antistaphylococcal immunoglobulin E antibodies in atopic dermatitis. J Clin Microbiol. 1985; 22:452–454.

20. Kim KH, Hwang JH, Park KC. Periauricular eczematization in childhood atopic dermatitis. Pediatr Dermatol. 1996; 13:278–280.

21. Hauser C, Wuethrich B, Matter L, Wilhelm JA, Sonnabend W, Schopfer K. Staphylococcus aureus skin colonization in atopic dermatitis patients. Dermatologica. 1985; 170:35–39.

22. Goh CL, Wong JS, Giam YC. Skin colonization of Staphylococcus aureus in atopic dermatitis patients seen at the National Skin Centre, Singapore. Int J Dermatol. 1997; 36:653–657.

23. Arslanagic N, Arslanagic R. Atopic dermatitis and Staphylococcus aureus. Med Arh. 2004; 58:363–365.

24. Lebon A, Labout JA, Verbrugh HA, Jaddoe VW, Hofman A, van Wamel WJ, van Belkum A, Moll HA. Role of Staphylococcus aureus nasal colonization in atopic dermatitis in infants: the Generation R Study. Arch Pediatr Adolesc Med. 2009; 163:745–749.

25. Skov L, Halkjaer LB, Agner T, Frimodt-Moller N, Jarlov JO, Bisgaard H. Neonatal colonization with Staphylococcus aureus is not associated with development of atopic dermatitis. Br J Dermatol. 2009; 160:1286–1291.

26. Hoeger PH, Lenz W, Boutonnier A, Fournier JM. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis. 1992; 165:1064–1068.

27. Bonness S, Szekat C, Novak N, Bierbaum G. Pulsed-field gel electrophoresis of Staphylococcus aureus isolates from atopic patients revealing presence of similar strains in isolates from children and their parents. J Clin Microbiol. 2008; 46:456–461.

28. Pournaras CC, Lubbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J Invest Dermatol. 2001; 116:480–481.

29. Remitz A, Kyllonen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001; 107:196–197.

30. Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol. 1994; 131:536–540.

31. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 1992; 27:29–34.

32. Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol. 2001; 116:658–663.

33. Cho SH, Strickland I, Boguniewicz M, Leung DY. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol. 2001; 108:269–274.

34. Sator PG, Schmidt JB, Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol. 2003; 48:352–358.

35. Kita K, Sueyoshi N, Okino N, Inagaki M, Ishida H, Kiso M, Imayama S, Nakamura T, Ito M. Activation of bacterial ceramidase by anionic glycerophospholipids: possible involvement in ceramide hydrolysis on atopic skin by Pseudomonas ceramidase. Biochem J. 2002; 362(Pt 3):619–626.

36. Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol. 2002; 119:433–439.

37. Akiyama H, Toi Y, Kanzaki H, Tada J, Arata J. Prevalence of producers of enterotoxins and toxic shock syndrome toxin-1 among Staphylococcus aureus strains isolated from atopic dermatitis lesions. Arch Dermatol Res. 1996; 288:418–420.

38. Bunikowski R, Mielke M, Skarabis H, Herz U, Bergmann RL, Wahn U, Renz H. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol. 1999; 103(1 Pt 1):119–124.

39. McFadden JP, Noble WC, Camp RD. Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol. 1993; 128:631–632.

40. Breuer K, Wittmann M, Bosche B, Kapp A, Werfel T. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy. 2000; 55:551–555.

41. Bunikowski R, Mielke ME, Skarabis H, Worm M, Anagnostopoulos I, Kolde G, Wahn U, Renz H. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol. 2000; 105:814–819.

42. Zollner TM, Wichelhaus TA, Hartung A, Von Mallinckrodt C, Wagner TO, Brade V, Kaufmann R. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy. 2000; 30:994–1000.

43. Roll A, Cozzio A, Fischer B, Schmid-Grendelmeier P. Microbial colonization and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2004; 4:373–378.

44. Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol. 2000; 105:782–787.

45. Takai T, Ikeda S. Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases. Allergol Int. 2011; 60:25–35.

46. Dubin G. Extracellular proteases of Staphylococcus spp. Biol Chem. 2002; 383:1075–1086.

47. Kantyka T, Shaw LN, Potempa J. Papain-like proteases of Staphylococcus aureus. Adv Exp Med Biol. 2011; 712:1–14.

48. Hirasawa Y, Takai T, Nakamura T, Mitsuishi K, Gunawan H, Suto H, Ogawa T, Wang XL, Ikeda S, Okumura K, Ogawa H. Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J Invest Dermatol. 2010; 130:614–617.

49. Schnopp C, Ring J, Mempel M. The role of antibacterial therapy in atopic eczema. Expert Opin Pharmacother. 2010; 11:929–936.

50. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010; 163:12–26.

51. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009; 123:e808–e814.

52. Walling HW, Swick BL. Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol. 2010; 3:99–117.

53. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol. 2001; 108:651–652.

54. Brockow K, Grabenhorst P, Abeck D, Traupe B, Ring J, Hoppe U, Wolf F. Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus-aureus-colonized atopic eczema. Dermatology. 1999; 199:231–236.

55. Gomes PL, Malavige GN, Fernando N, Mahendra MH, Kamaladasa SD, Seneviratne JK, Karunatilaka DH, Ogg GS. Characteristics of Staphylococcus aureus colonization in patients with atopic dermatitis in Sri Lanka. Clin Exp Dermatol. 2011; 36:195–200.

56. Heng YK, Tan KT, Sen P, Chow A, Leo YS, Lye DC, Chan RK. Staphylococcus aureus and topical fusidic acid use: results of a clinical audit on antimicrobial resistance. Int J Dermatol. 2013; 52:876–881.

57. Petry V, Lipnharski C, Bessa GR, Silveira VB, Weber MB, Bonamigo RR, d'Azevedo PA. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus and antibiotic resistance in patients with atopic dermatitis in Porto Alegre, Brazil. Int J Dermatol. 2014; 53:731–735.

58. Kedzierska A, Kapinska-Mrowiecka M, Czubak-Macugowska M, Wojcik K, Kedzierska J. Susceptibility testing and resistance phenotype detection in Staphylococcus aureus strains isolated from patients with atopic dermatitis, with apparent and recurrent skin colonization. Br J Dermatol. 2008; 159:1290–1299.

59. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev. 2008; (3):CD003871.

60. Howden BP, Grayson ML. Dumb and dumber: the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis. 2006; 42:394–400.

61. Heggers JP, Sazy JA, Stenberg BD, Strock LL, McCauley RL, Herndon DN, Robson MC. Bactericidal and wound-healing properties of sodium hypochlorite solutions: the 1991 Lindberg Award. J Burn Care Rehabil. 1991; 12:420–424.

62. Sassone LM, Fidel RA, Murad CF, Fidel SR, Hirata R Jr. Antimicrobial activity of sodium hypochlorite and chlorhexidine by two different tests. Aust Endod J. 2008; 34:19–24.

63. McKenna PJ, Lehr GS, Leist P, Welling RE. Antiseptic effectiveness with fibroblast preservation. Ann Plast Surg. 1991; 27:265–268.

64. Fisher RG, Chain RL, Hair PS, Cunnion KM. Hypochlorite killing of community-associated methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2008; 27:934–935.

65. Winter J, Ilbert M, Graf PC, Ozcelik D, Jakob U. Bleach activates a redox-regulated chaperone by oxidative protein unfolding. Cell. 2008; 135:691–701.

66. Ryan C, Shaw RE, Cockerell CJ, Hand S, Ghali FE. Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis. Pediatr Dermatol. 2013; 30:308–315.

67. Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. J Dermatol. 2013; 40:874–880.

68. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, Murray PR, Turner ML, Segre JA. NISC Comparative Sequence Program. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012; 22:850–859.

69. Tan WP, Suresh S, Tey HL, Chiam LY, Goon AT. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis. Clin Exp Dermatol. 2010; 35:e109–e112.

70. Jensen JM, Pfeiffer S, Witt M, Brautigam M, Neumann C, Weichenthal M, Schwarz T, Folster-Holst R, Proksch E. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009; 123:1124–1133.

71. Abramovits W. A clinician's paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol. 2005; 53:1 Suppl 1. S70–S77.

72. Hung SH, Lin YT, Chu CY, Lee CC, Liang TC, Yang YH, Wang LC, Chiang BL. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol. 2007; 98:51–56.

73. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012; 24:253–260.

74. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis: an emerging concept. Allergy. 2009; 64:276–278.